Adoptive Cell Transfer of Allogeneic Epstein-Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report.
Adoptive Transfer
/ adverse effects
Allogeneic Cells
/ immunology
Epstein-Barr Virus Infections
/ complications
Female
Heart Transplantation
/ adverse effects
Herpesvirus 4, Human
/ immunology
Humans
Lymphoproliferative Disorders
/ etiology
Smooth Muscle Tumor
/ complications
T-Lymphocytes
/ immunology
Transplantation, Homologous
Treatment Outcome
Viremia
/ complications
Young Adult
PTSMT
T-cell transfer
adoptive cell transfer
alloCELL
case report
posttransplant smooth muscle tumors
smooth muscle tumor
virus-specific T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
06
2021
accepted:
01
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
11
2
2022
Statut:
epublish
Résumé
Posttransplant smooth muscle tumors (PTSMTs) are rare Epstein-Barr virus (EBV)-associated neoplasms, mostly occurring after solid organ transplantation. Current therapeutic strategies include surgery and reduction of immunosuppressive medication. We describe for the first time a novel treatment approach for PTSMT by adoptive cell transfer (ACT) of EBV-specific T cells to a 20-year-old patient with a medical history of cardiac transplantation, posttransplant lymphoproliferative disease, and multilocular PTSMT. During ACT, mild cytokine release syndrome occurred, while no unexpected safety signals were recorded. We observed
Identifiants
pubmed: 34925312
doi: 10.3389/fimmu.2021.727814
pmc: PMC8677671
doi:
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
727814Informations de copyright
Copyright © 2021 Hansen, Bacher, Eiz-Vesper, Heckl, Klapper, Koch, Maecker-Kolhoff, Baldus and Fransecky.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2018 Jun 27;9:1475
pubmed: 29997626
Transpl Infect Dis. 2018 Apr;20(2):e12841
pubmed: 29359839
Transplantation. 2010 Jul 15;90(1):93-4
pubmed: 20606564
Lancet Oncol. 2006 Nov;7(11):955-7
pubmed: 17081922
Protein Sci. 2003 May;12(5):1007-17
pubmed: 12717023
J Microsc Ultrastruct. 2020 Nov 09;9(1):41-44
pubmed: 33850712
Clin Immunol. 2020 May;214:108382
pubmed: 32169439
Blood. 2005 Dec 15;106(13):4397-406
pubmed: 16123217
Immunogenetics. 1999 Nov;50(3-4):213-9
pubmed: 10602881
Front Med (Lausanne). 2019 Dec 18;6:295
pubmed: 31921871
Blood. 2013 May 2;121(18):3745-58
pubmed: 23435462
Blood. 2013 Jun 27;121(26):5113-23
pubmed: 23610374
Kidney Int Suppl (2011). 2012 Mar;2(1):8-12
pubmed: 25018916
Am J Transplant. 2020 Sep;20(9):2457-2465
pubmed: 32027461
Blood. 2010 Feb 4;115(5):925-35
pubmed: 19880495
Leuk Lymphoma. 1997 Oct;27(3-4):303-14
pubmed: 9402327
Nat Med. 2007 Jun;13(6):748-53
pubmed: 17496901
JACC Basic Transl Sci. 2016 Jan-Feb;1(1-2):49-60
pubmed: 27127803
J Virol. 1992 Jan;66(1):122-31
pubmed: 1309242
Am J Respir Crit Care Med. 2015 Feb 1;191(3):348-52
pubmed: 25635493
Transplant Proc. 2005 May;37(4):1839-44
pubmed: 15919482
J Heart Lung Transplant. 2007 Jul;26(7):753-5
pubmed: 17613410
N Engl J Med. 1995 Jan 5;332(1):12-8
pubmed: 7990860
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
Intensive Care Med. 2018 Mar;44(3):371-373
pubmed: 28956093
Transpl Infect Dis. 2020 Feb;22(1):e13201
pubmed: 31643129
Cytotherapy. 2018 Jun;20(6):830-838
pubmed: 29753677
Int J Mol Sci. 2018 Dec 08;19(12):
pubmed: 30544783
Immunity. 2020 Dec 15;53(6):1258-1271.e5
pubmed: 33296686
Am J Transplant. 2012 Jul;12(7):1908-17
pubmed: 22420456
Cell. 2016 Nov 3;167(4):1067-1078.e16
pubmed: 27773482
Clin Cancer Res. 2009 Sep 1;15(17):5350-8
pubmed: 19706821
Clin Transplant. 2013 Jul-Aug;27(4):E462-8
pubmed: 23682851
J Heart Lung Transplant. 2009 Nov;28(11):1217-20
pubmed: 19783183
Expert Rev Anticancer Ther. 2018 Oct;18(10):981-989
pubmed: 29995451
Am J Transplant. 2008 Jan;8(1):253-8
pubmed: 18184312
J Immunol. 2013 Apr 15;190(8):3967-76
pubmed: 23479226
Dig Dis Sci. 2014 Jul;59(7):1630-7
pubmed: 24464209
J Immunother. 2018 Apr;41(3):158-163
pubmed: 29239916
J Cutan Pathol. 2021 Feb;48(2):325-329
pubmed: 33245561
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
J Transl Med. 2014 Dec 16;12:336
pubmed: 25510656
Arch Pathol Lab Med. 2016 Jul;140(7):718-22
pubmed: 27362573
Eur Rev Med Pharmacol Sci. 2003 Jul-Aug;7(4):107-9
pubmed: 15068233
Cell. 2019 Mar 7;176(6):1340-1355.e15
pubmed: 30799037
N Engl J Med. 1995 Jan 5;332(1):19-25
pubmed: 7990861
Transpl Infect Dis. 2013 Oct;15(5):E182-6
pubmed: 24034213
Br J Haematol. 2006 Jul;134(1):64-76
pubmed: 16803570
Virchows Arch. 2004 Apr;444(4):387-91
pubmed: 15143769
J Hematol Oncol. 2019 Feb 6;12(1):13
pubmed: 30728058
Eur J Cancer. 2014 Sep;50(14):2417-24
pubmed: 25027306
Am J Surg Pathol. 1996 Dec;20(12):1511-9
pubmed: 8944045
Drug Discov Today. 2015 Oct;20(10):1243-9
pubmed: 26050578
Annu Rev Pathol. 2019 Jan 24;14:29-53
pubmed: 30125149
Biochem Pharmacol. 2009 Apr 1;77(7):1206-12
pubmed: 19154728